Grant: Canada Postdoctoral Research Award (CPRA) program
Direct Payment
$140,000.00
Synergistic innate immune responses to amyloid beta and pathogen-associated molecular patterns to accelerate Alzheimer's disease progression
FY 2025-26
Summary
Alzheimer's disease is a form of dementia that involves progressive loss of brain function, leading to serious memory loss. A feature that separates Alzheimer's from other forms of dementia is the accumulation of a protein called amyloid beta (AB) within the brain. AB causes inflammation in the brain as it engages immune cells similarly to bacteria and viruses. Strikingly, individuals that have suffered from a serious infection that required hospitalization are nearly twice as likely to eventually develop Alzheimer's. This suggests that extreme immune activation, due to a severe infection, is correlated with symptom onset. The purpose of the proposed research is to identify how infections could enhance inflammation in the brain caused by AB. To achieve this, I will treat isolated immune cells and brain cells with AB in combination with purified components of bacteria and viruses and measure the inflammatory response. I will also infect genetically modified Alzheimer's mice with influenza virus or pneumonia-causing bacteria at an age where AB first accumulates. Several months later, the cognitive function of these mice will be thoroughly tested and the levels of AB and inflammation within their brains will be measured. We expect that the mice that experience an infection will exhibit much faster onset of Alzheimer's symptoms and greater inflammation in their brains. By using isolated cells and purified components from pathogens, we hope to identify the specific elements of the infection that are responsible for this effect which would help to predict pathogen-specific risk. Strategies for the treatment of Alzheimer's have largely been restricted to drugs that reduce AB, however, this strategy is expensive and not very effective. We hope to set the stage for future therapies to minimize inflammation in the brain and prevent the onset of symptoms completely by targeting the inflammatory processes that are initiated by AB and amplified during infection.
Department
Program
Canada Postdoctoral Research Award (CPRA) program
Recipient
Location
Tennessee, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
537487
Name
Young Alexander P
Region
Tennessee
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Synergistic innate immune responses to amyloid beta and pathogen-associated molecular patterns to accelerate Alzheimer's disease progression
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Alzheimer'S Disease; Infection; Inflammasomes; Innate Immunity; Macrophages; Neuroinflammation; Toll-Like Receptors
Abstract
Alzheimer's disease is a form of dementia that involves progressive loss of brain function, leading to serious memory loss. A feature that separates Alzheimer's from other forms of dementia is the accumulation of a protein called amyloid beta (AB) within the brain. AB causes inflammation in the brain as it engages immune cells similarly to bacteria and viruses. Strikingly, individuals that have suffered from a serious infection that required hospitalization are nearly twice as likely to eventually develop Alzheimer's. This suggests that extreme immune activation, due to a severe infection, is correlated with symptom onset. The purpose of the proposed research is to identify how infections could enhance inflammation in the brain caused by AB. To achieve this, I will treat isolated immune cells and brain cells with AB in combination with purified components of bacteria and viruses and measure the inflammatory response. I will also infect genetically modified Alzheimer's mice with influenza virus or pneumonia-causing bacteria at an age where AB first accumulates. Several months later, the cognitive function of these mice will be thoroughly tested and the levels of AB and inflammation within their brains will be measured. We expect that the mice that experience an infection will exhibit much faster onset of Alzheimer's symptoms and greater inflammation in their brains. By using isolated cells and purified components from pathogens, we hope to identify the specific elements of the infection that are responsible for this effect which would help to predict pathogen-specific risk. Strategies for the treatment of Alzheimer's have largely been restricted to drugs that reduce AB, however, this strategy is expensive and not very effective. We hope to set the stage for future therapies to minimize inflammation in the brain and prevent the onset of symptoms completely by targeting the inflammatory processes that are initiated by AB and amplified during infection.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Young, Alexander P
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~